Update July 22, 2021: The European Union has added Guillain-Barré syndrome, an autoimmune paralysis disorder, as a possible side effect of Johnson and Johnson’s Covid-19 vaccine.
Update July 12, 2021: The FDA added warnings about Guillain-Barre autoimmune paralysis, in which the immune system attacks the body’s nerves, after the Johnson and Johnson vaccine. According to reports, cases were mostly reported about two weeks after vaccination, mainly in men and “any age 50 or older”.
Numerous clinical cases of Guillain-Barre syndrome
Paralysis after the Covid-19 vaccine have prompted scientists to warn that “all doctors” should be “vigilant in recognizing Guillain-Barré syndrome in patients who have received the AstraZeneca vaccine .
“Our observations suggest that this clinically distinct variant [Guillain-Barré syndrome] is more severe than usual and may require mechanical ventilation.”In the UK, scientists reported “bifacial weakness and normal facial sensation in four men between 11 and 22 days after their first doses of the Astra-Zeneca vaccine.”
A case was also reported in a patient who received the Pfizer vaccine. In India, there are reports of seven severe cases of Guillain-Barré syndrome 10 to 14 days after the first dose of AstraZeneca’s vaccine.
Six were women, all had facial paralysis, “all progressed to quadriplegia and six required respiratory support. The age of the patients ranged from 43 to 70 years. Four developed other cranial neuropathies, including abducens palsy and involvement of the trigeminal sensory nerve.Guillain-Barre syndrome has been reported after other vaccinations.
Damage to the immune system is believed to be the cause. The disorder can be extremely serious and can lead to total paralysis with dependence on artificial respiration. Even those who recover may have severe muscle wasting and may have to slowly teach the body to relearn most of every normal task, such as walking. One in 20 cases is fatal.
Updated December 24, 2021: A Danish study found that people “significantly increased risk” or heart inflammation after the Moderna and Pfizer Covid-19 vaccination “mainly driven by an increase in risk among individuals aged 12 and 39 years “.Updated December 14, 2021:
A UK study found people at increased risk of heart inflammation
Updated November 21, 2021: an analysis presented to the American Heart Association and published in the journal Cardiology warns of a “dramatic” increase in heart risk for most people who have received the Covid-19 mRNA vaccine.
Updated November 14, 2021: Taiwan’s health minister announced the temporary suspension of the second dose of Covid-19 vaccine for children due to concerns about heart inflammation of myocarditis. Pfizer is the vaccine administered in Taiwan.
- Updated November 10, 2021: A German advisory committee says Moderna vaccine should not be used in people under 30 or pregnant women because it causes more cases of heart inflammation than Pfizer.
- Moderna’s rate of heart inflammation in young men was nearly three times that reported after Pfizer. Some health authorities have reported heart problems with both vaccines.
Updated on 10 October 2021: Iceland joins Finland, Sweden and Denmark in the break from Moderna due to an increase in heart problems such as myocarditis and pericarditis. While some of the countries are allowing Moderna in people over the age of 30, Iceland does not allow its use at all at the moment.